Fubotv earnings beat by $0.10, revenue topped estimates
BOCA RATON - INmune Bio Inc. (NASDAQ:INMB), a clinical-stage inflammation and immunology company with a market capitalization of $146 million, has secured agreements with two healthcare-focused institutional investors to sell 3,000,000 shares of common stock in a registered direct offering priced at $6.30 per share, the company announced Friday. According to InvestingPro data, the company holds more cash than debt on its balance sheet, maintaining a healthy current ratio of 2.64x.
The offering, priced at-the-market under Nasdaq rules, is expected to close around June 30, 2025, subject to customary closing conditions. The transaction is anticipated to generate approximately $19 million in gross proceeds before deducting placement agent fees and other offering expenses. The timing of this capital raise comes as the stock has shown significant momentum, with InvestingPro reporting a 35% price return over the past six months despite recent market volatility.
INmune Bio plans to use the net proceeds for working capital and general corporate purposes, according to the company’s statement. A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction.
The offering is being conducted under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission.
INmune Bio focuses on developing treatments targeting the innate immune system to combat disease. The company currently has three product platforms in clinical trials: XPro for neurological conditions, INKmune for cancer treatment, and CORDStrom for recessive dystrophic epidermolysis bullosa. Analysts maintain an optimistic outlook, with price targets ranging from $20 to $30 per share, significantly above current trading levels. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro.
The company’s announcement noted that its clinical trials are in early stages, and there is no assurance of specific outcomes. The information in this article is based on a press release statement from INmune Bio.
In other recent news, INmune Bio Inc. reported a narrowed net loss of $9.7 million for Q1 2025, improving from an $11 million loss in the same period last year. The company’s earnings per share (EPS) exceeded expectations, with an actual EPS of -$0.43 compared to the forecasted -$0.49. INmune Bio is set to present top-line data from its Phase 2 MINDFuL clinical trial for Alzheimer’s disease, which is a significant upcoming event for the company. The trial involves the XPro treatment, which targets neuroinflammation in early Alzheimer’s patients. Lucid Capital Markets initiated coverage on INmune Bio with a Buy rating, citing the pressing need for effective Alzheimer’s treatments. Additionally, a study presented at the Keystone Symposia indicated that XPro could reduce Alzheimer’s-like pathology in mice following traumatic brain injury. This research highlights the potential of XPro in addressing neurobehavioral dysfunctions related to brain trauma and aging. These developments come as the company prepares for a conference call to discuss the upcoming trial data, which could significantly impact its future in the Alzheimer’s treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.